REG - AstraZeneca PLC - Annual Financial Report <Origin Href="QuoteRef">AZN.L</Origin> - Part 22
08/03/2016 12:11
- Part 22: For the preceding part double click ID:nRSH4027Ru
trade.
Increasing implementation and enforcement of more stringent anti-bribery Impact
and anti-corruption legislation
There is an increasing global focus on the implementation and enforcement Despite taking measures to prevent breaches of applicable anti-bribery and anti-corruption laws by our personnel and associated third parties, breaches may still occur, potentially resulting in the imposition of significant penalties, such as fines, the requirement to comply with monitoring or self-reporting obligations, or debarment or exclusion from government sales or reimbursement programmes, any of which could materially adversely affect our reputation, business or results of operations.
of anti-bribery and anti-corruption legislation.For example, in the UK,
the Bribery Act 2010 has extensive extra-territorial application, and
imposes organisational liability for any bribe paid by persons or
entities associated with an organisation where the organisation failed to
have adequate preventative controls in place at the time of the offence.
In the US, there has been significant enforcement activity in respect of
the Foreign Corrupt Practices Act by the SEC and DOJ against US companies
and non-US companies listed in the US. China and other countries are also
- More to follow, for following part double click ID:nRSH4027RwRecent news on AstraZeneca
See all newsREG - AstraZeneca PLC - Notification of Admission of Shares
AnnouncementREG - AstraZeneca PLC - Imfinzi approved in EU for early gastric cancer
AnnouncementREG - AstraZeneca PLC - Notice of AGM
AnnouncementRCS - Redx Pharma Limited - RXC008 Receives US FDA Fast Track Designation
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
Announcement